Guida Cesare, Maione Paolo, Rossi Antonio, Bareschino Marianna, Schettino Clorinda, Barzaghi Domenico, Elmo Massimo, Gridelli Cesare
Division of Radiotherapy, S.G. Moscati Hospital, Avellino, Italy.
Crit Rev Oncol Hematol. 2008 Dec;68(3):222-32. doi: 10.1016/j.critrevonc.2008.05.007. Epub 2008 Jul 15.
Currently, combinations of chemotherapy and radiotherapy are the standard treatment approach for locally advanced NSCLC patients. Concomitant chemo-radiotherapy, although associated with increased acute toxicity, has demonstrated to be the better strategy over sequential chemoradiotherapy, and it is to be considered a standard approach in patients with good performance status (0-1). However, the approach to locally advanced NSCLC and to chemo-radiotherapy regimens remains heterogeneous among oncologists, and clinical outcomes are yet disappointing. Thus, the search of new strategies is mandatory. The main fields of research aiming at improving the survival of locally advanced NSCLC patients are: the addition of further combination chemotherapy as induction or consolidation to concurrent chemo-radiotherapy, and the integration of molecularly targeted therapies into conventional chemo-radiotherapy regimens.
目前，化疗和放疗联合是局部晚期非小细胞肺癌（NSCLC）患者的标准治疗方法。同步放化疗虽与急性毒性增加相关，但已证明比序贯放化疗更具优势，对于身体状况良好（0 - 1）的患者应被视为标准方法。然而，肿瘤学家对局部晚期NSCLC的治疗方法和放化疗方案仍存在差异，临床结果也不尽人意。因此，寻求新策略势在必行。旨在提高局部晚期NSCLC患者生存率的主要研究领域包括：在同步放化疗基础上增加进一步的联合化疗作为诱导或巩固治疗，以及将分子靶向治疗纳入传统放化疗方案。
